ALC
Stock Details
ALC is Alcon Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 75.12$. Average daily volumn in 3 months 906.94k. Market cap 36.81B
Stock symbol : ALC. Exchange : NYSE. Currency : USD Lastest price : 75.11$. Total volume : 665.29k. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Alcon Inc. (ALC)
Last Price
75.11$Change
1.49Volume
665.29k
| Previous Close | 73.62 |
| Open | 74.33 |
| Day Range | 74.34-75.43 |
| Bid | 75.02 x 1.4k |
| Ask | 77.01 x 900 |
| Volume | 665.29k |
| Average Volume | 906.94k |
| Market Cap | 36.81B |
| Beta | 0.60 |
| 52 Week Range | 63.92-88.78 |
| Trailing P/E | 80.76 |
| Foward P/E | 31.17 |
| Dividend (Yield %) | 0.28% |
| Ex-Dividend Date | 2022-05-03 |
Financial Details
Organization
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion ... vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Market Cap:
36.81BRevenue:
8.29BTotal Assets:
28BTotal Cash:
1.57B
News about "Alcon Inc."
Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
Source from : YAHOO!Finance - 5 days ago
Expands ophthalmic eye drop portfolio leveraging market access expertise and newly created US ophthalmic eye drop sales force. EYSUVIS complements Systane Preservative-Free by exp ...See details»
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
Source from : Nasdaq - 5 days ago
Alcon Inc. ALC recently inked a deal to acquire EYSUVIS (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals, Inc. The acquisition adds to Alcon’s Systane family ...See details»
The week in bankruptcies: Alcon Contractors and Beacon Cookie Cafe
Source from : The Business Journals - 2 days ago
This week in San Antonio business bankruptcies include Alcon Contractors LLC and Beacon Cookie Cafe Inc.. For the year, San Antonio has recorded 18 business bankruptcy filings.See details»
Alcon Prices EUR 500.0 Million Senior Notes Offering
Source from : YAHOO!Finance - 4 days ago
(SIX/NYSE: ALC), today announced that it has commenced and priced a public offering of EUR 500 million aggregate principal amount of its 2.375% senior notes due 2028 (the "Notes"). The Notes will be ...See details»
Alcon To Acquire EYSUVIS, INVELTYS From Kala Pharma
Source from : Nasdaq - 5 days ago
Alcon (ALC) said it agreed to acquire EYSUVIS (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals Inc. EYSUVIS was approved by the U.S. Food & Drug ...See details»
Alcon to Acquire Eysuvis Drops for Dry Eye Treatment
Source from : INVISIONMAG - 4 days ago
Alcon has signed an agreement to acquire Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals Inc. The acquisition of the eye drops (0.25% loteprednol etabonate suspension) “will complement ...See details»
Alcon Inc. (ALC) CEO David Endicott on Q1 2022 Results - Earnings Call Transcript
Source from : Seeking Alpha - 17 days ago
Greetings and welcome to the Alcon First Quarter 2022 Earnings Conference. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.See details»
Alcon Announces Results of 2022 Annual General Meeting
Source from : Morningstar%2c Inc. - 1 month ago
Bono as newly-elected member of the Board Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed ...See details»
Alcon Celebrates 75 Years of Eye Care Innovation and Access with Brilliant History. Brilliant Future.
Source from : INVISIONMAG - 11 days ago
Brilliant Future. celebration. On May 16, 1947, Alcon Laboratories, Inc. was incorporated and began manufacturing specialty pharmaceutical products in Fort Worth, Texas. Today, Alcon has complementary ...See details»
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
Source from : Yahoo Sport Australia - 5 days ago
Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease Persistent ...See details»
Corneal Implants Market is reaching US$ 68.4 Mn with CAGR of 13% in 2029|Alcon, Inc., CorneaGen, Aurolab and more
Source from : Medgadget - 22 days ago
The use of corneal implants is gathering momentum around the world, owing to their proven efficacy for the correction of presbyopia by improving near and intermediate vision without any ...See details»
Alcon Inc. Swiss: Alcon Reports First Quarter 2022 Results
Source from : Finanznachrichten - 17 days ago
53 LR Regulaotry News: Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the first quarter ended March 31, 2022. For the first quarter of 2022, worldwide ...See details»
Phacoemulsification Devices Market Share to Grow by USD 559.66 million | 38% of Market Growth to Originate from North America | Technavio
Source from : Benzinga.com - 26 days ago
Alcon Inc., Bausch Health Companies Inc., Carl Zeiss AG, Glaukos Corp., Haag-Streit AG, HOYA Corp., HumanOptics Holding AG, Lenstec Inc., LIGHTMED Corp., LUMed ...See details»
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
Source from : Yahoo Sport Australia - 18 days ago
Alcon Inc. ALC is expected to report first-quarter 2022 results on May 10, following market close. In the last-reported quarter, the company’s earnings per share (EPS) of 56 cents beat the Zacks ...See details»